ANG003 Dose A

Phase 2

TherapeuticsMD, Inc. (TXMD)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Jul '27

TXMDPhase 2$25M

ANG003 Dose A Phase 2 Est. Readout

ANG003 Dose A• Exocrine Pancreatic Insufficiency (EPI)113

Jul 2027~ConfirmedSTALE

CT.gov

00%

Competitive Landscape

0 competitors in Exocrine Pancreatic Insufficiency (EPI)

View Full Landscape

Drug Information

Target Indication

Exocrine Pancreatic Insufficiency (EPI)

Clinical Trial

NCT07450547

Last updated: 6/28/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

TXMD

TherapeuticsMD, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

KarXTPhase 3

Psychosis Associated With Alzheimer's Disease

DexycuPhase 3

Inflammation

enclomiphene citratePhase 3

Effect of Treatment on Bone Mineral Density

REL-1017Phase 3

Major Depressive Disorder

ETC-1002Phase 3

Hypercholesterolemia

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts